Molecular Characterization of Candida Auris

Oral Fungal Infection Clinical Trial

— OC  

Official title:

Formulation Development and In-Vitro Studies of Efficacy of Botanical Extracts Against Candida Auris

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04121871
• Other study ID #: Oral Fungal Infection
• Status: Completed
• Start date: November 15, 2019
• Est. completion date: February 29, 2020

Study information

• Verified date: October 2020
• Source: Islamia University of Bahawalpur
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Candida auris is emerging fungal opportunistic pathogen in developing countries. Much studies has been conducted on Candida albicans. there was a dire need to investigate this alarming threat. Our hypothesis is that by recording the patients diagnosed with oropharygneal candidiasis and collecting clinical swab samples from these patients will be fruitful if microbiological isolation, identification and molecular characterization will be done. So this is the first study on C. auris in south punjab, Pakistan. Aim of this study is to collect epidemiological data of C. auris.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 384
• Est. completion date: February 29, 2020
• Est. primary completion date: February 29, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 100 Years

Eligibility

Inclusion Criteria:

• Pre-diagnosed Patients of both gender from pre-selected localities

Exclusion Criteria:

• Healthy individuals or individuals having no oral fungal infection individuals above 100 years of age

Related Conditions & MeSH terms

• Mycoses
• Oral Fungal Infection

Intervention

Other:
• No intervention
Not required

Locations

Country	Name	City	State
Pakistan	Bahawal Victoria Hospital Bahawalpur	Bahawalpur	Punjab
Pakistan	Civil Hospital Jhangi Wala Road Bahawalpur	Bahawalpur	Punjab

Sponsors (1)

Lead Sponsor	Collaborator
Islamia University of Bahawalpur

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of C. auris	patients from selected localities will be recorded along with total patients in that category, prevalence will be calculated on the record collected from specified duration of study	From November 15, 2019 to February 29, 2020
Primary	Seasonality of C. auris infection	Number of patients recorded during different months will be the source of calculation of seasonality index of the C. auris infection	From November 15, 2019 to February 29, 2020
Primary	Drug susceptibility	Antifungal drug discs will be used for assessing the antfungal drugs susceptibility	From November 15, 2019 to February 29, 2020